|
Index | - | P/E | - | EPS (ttm) | - | Insider Own | - | Shs Outstand | 5.64M | Perf Week | -8.26% |
Market Cap | 58.45M | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 0.26M | Perf Month | -10.29% |
Income | - | PEG | - | EPS next Q | - | Inst Own | 0.42% | Short Float | 1.62% | Perf Quarter | -2.33% |
Sales | - | P/S | - | EPS this Y | - | Inst Trans | - | Short Ratio | 0.03 | Perf Half Y | 12.84% |
Book/sh | - | P/B | - | EPS next Y | - | ROA | - | Target Price | - | Perf Year | - |
Cash/sh | - | P/C | - | EPS next 5Y | - | ROE | - | 52W Range | 6.19 - 37.52 | Perf YTD | -22.61% |
Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -72.36% | Beta | - |
Dividend % | - | Quick Ratio | - | Sales past 5Y | - | Gross Margin | - | 52W Low | 67.53% | ATR | 0.67 |
Employees | 19 | Current Ratio | - | Sales Q/Q | -79.90% | Oper. Margin | - | RSI (14) | 40.70 | Volatility | 7.42% 5.11% |
Optionable | No | Debt/Eq | - | EPS Q/Q | - | Profit Margin | - | Rel Volume | 0.24 | Prev Close | 10.95 |
Shortable | Yes | LT Debt/Eq | - | Earnings | - | Payout | - | Avg Volume | 124.15K | Price | 10.37 |
Recom | - | SMA20 | -10.48% | SMA50 | -13.75% | SMA200 | -9.55% | Volume | 29,399 | Change | -5.30% |
![]() | ||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. to develop mGluR2PAM compounds for the treatment of human health. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland. | ||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||
![]() |
open in yahoo | open in reuters | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite